AXGN

Axogen Inc

49.25

Oct 28 • 3:59 PM ET +11.79 (31.47%)

49.20

Aftermarket • 7:53 PM ET -0.05 (-0.10%)

Healthcare Medical Devices USA Mid NASD

Oct 28, 1:47 PMAxogen beats Q3 revenue estimates with $75.8M (+26% YoY), raises FY26 revenue outlook to ≥$290M and adds BioCircuit NerveTape

Peers: IART BVS AORT CNMD LIVN MDXG OFIX VCEL SYK ORGO

| Held by: VTI IWM VXF IWO VTWO FESM SCHA IHI DFAS PSC

Scroll to Statements

Index	RUT
Market Cap	2.89B
Enterprise Value	2.56B
Income	-31.92M
Sales	266.93M
Book/sh	8.31
Cash/sh	5.97
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Jan 27, 2010
Dividend Gr. 3/5Y	- -
Payout	-
Employees	622
IPO	Dec 17, 1986

P/E	-
Forward P/E	66.95
PEG	1.27
P/S	10.83
P/B	5.93
P/C	8.25
P/FCF	121.61
EV/EBITDA	-
EV/Sales	9.59
Quick Ratio	10.67
Current Ratio	12.02
Debt/Eq	0.04
LT Debt/Eq	0.04
Option/Short	Yes / Yes

EPS (ttm)	-0.65
EPS next Y	0.74
EPS next Q	0.15
EPS this Y	82.98%
EPS next Y	38.63%
EPS next 5Y	52.51%
EPS past 3/5Y	20.86% 10.54%
Sales past 3/5Y	17.57% 14.93%
EPS Y/Y TTM	-1274.47%
Sales Y/Y TTM	24.32%
EPS Q/Q	163.19%
Sales Q/Q	26.22%
Earnings	Oct 28 BMO
EPS/Sales Surpr.	59.94% 3.63%

Insider Own	2.45%
Insider Trans	-8.67%
Inst Own	96.44%
Inst Trans	7.04%
ROA	-8.33%
ROE	-10.35%
ROIC	-6.21%
Gross Margin	74.18%
Oper. Margin	-5.17%
Profit Margin	-11.96%
SMA20	32.18%
SMA50	15.12%
SMA200	25.05%
Trades

Shs Outstand	59.72M
Shs Float	57.23M
Short Float	8.95%
Short Ratio	4.07
Short Interest	5.12M
52W High	52.91 -6.92%
52W Low	17.14 187.34%
Volatility	6.01% 4.62%
ATR (14)	2.40
RSI (14)	74.47
Beta	1.24
Rel Volume	7.38
Avg Volume	1.26M
Volume	9,291,224

Perf Week	35.01%
Perf Month	16.05%
Perf Quarter	19.11%
Perf Half Y	17.91%
Perf YTD	50.47%
Perf Year	172.40%
Perf 3Y	1220.38%
Perf 5Y	225.51%
Perf 10Y	453.37%
Recom	1.33
Target Price	57.55
Prev Close	37.46
Price	49.25
Change %	31.47%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-12-26	Initiated	BofA Securities	Buy	$52
Oct-07-26	Initiated	Barclays	Overweight	$55
Aug-26-26	Initiated	Truist	Buy	$60
Feb-19-26	Initiated	Wells Fargo	Overweight	$40
Dec-01-25	Initiated	Mizuho	Outperform	$40
Mar-17-25	Initiated	Lake Street	Buy	$30
Jul-01-24	Initiated	Raymond James	Outperform	$13
Nov-11-22	Resumed	Jefferies	Buy	$15
May-09-22	Upgrade	Canaccord Genuity	Hold → Buy	$10 → $15
Mar-11-22	Resumed	Cantor Fitzgerald	Overweight	$21
Oct-23-20	Initiated	Guggenheim	Buy	$24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$16
May-07-20	Downgrade	Canaccord Genuity	Buy → Hold	$12
Apr-02-20	Downgrade	BTIG Research	Buy → Neutral
Aug-07-19	Downgrade	William Blair	Outperform → Mkt Perform
Jul-12-19	Initiated	Canaccord Genuity	Buy	$32
Mar-02-18	Reiterated	Lake Street	Buy	$26 → $38
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Nov-30-17	Initiated	Jefferies	Buy	$35
Nov-21-17	Reiterated	Lake Street	Buy	$22 → $26

Show Previous Ratings

Oct-28-26 02:36PM	AxoGen: Q3 Earnings Snapshot (Associated Press) +31.47%
10:50AM	Axogen Swings To GAAP Profit And Raises Guidance A Third Time, But Gross Margin Is The Weak Spot (Earnings Whispers)
07:02AM	Axogen, Inc. Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Oct-14-26 07:00AM	Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026 (GlobeNewswire)
Oct-07-26 10:00AM	Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls (The Fly)
05:19PM	Loading…
Oct-01-26 05:19PM	Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair (GlobeNewswire) -6.34%
Sep-10-26 10:47AM	2 Medical-Device Stocks Lighting Up the Options Pits (Schaeffer's Research) -11.47%
06:01AM	Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock (GlobeNewswire)
06:00AM	Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies (GlobeNewswire)
Sep-01-26 07:00AM	Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Jul-29-26 03:03PM	Axogen Inc (AXGN) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Margin Challenges (GuruFocus.com)
07:20AM	AxoGen: Q2 Earnings Snapshot (Associated Press)
07:05AM	Axogen, Inc. Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-21-26 08:22AM	Nvidia Returns to NZS Growth Fund (GuruFocus.com)
Jul-15-26 07:00AM	Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026 (GlobeNewswire)
07:00AM	Loading…
Apr-30-26 07:00AM	Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference (GlobeNewswire)
Apr-29-26 03:03AM	Axogen Inc (AXGN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses (GuruFocus.com)
Apr-28-26 07:11AM	AxoGen: Q1 Earnings Snapshot (Associated Press) +6.60%
07:00AM	Axogen, Inc. Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-14-26 07:00AM	Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026 (GlobeNewswire)
Mar-05-26 09:07PM	AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference (MarketBeat)
Feb-24-26 02:03PM	Axogen Inc (AXGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -8.14%
10:44AM	AxoGen Q4 Earnings Call Highlights (MarketBeat)
09:40AM	AxoGen (AXGN) Q4 Earnings Miss Estimates (Zacks)
07:32AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-19-26 07:01AM	Axogen (AXGN) Benefited from Multiple Tailwinds (Insider Monkey)
Feb-17-26 07:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Feb-10-26 07:00AM	Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (GlobeNewswire)
Jan-22-26 12:42PM	Axogen Prices Upsized $124 Million Stock Offering (Benzinga)
11:18PM	Loading…
Jan-21-26 11:18PM	Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock (GlobeNewswire)
04:09PM	Axogen Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-15-26 03:07PM	AxoGen Touts Post-BLA Growth Plan, 75%+ Gross Margin Outlook at J.P. Morgan Healthcare Conference (MarketBeat)
Jan-12-26 07:00AM	Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 (GlobeNewswire) -5.85%
Dec-17-25 07:00AM	Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire) +6.95%
Dec-03-25 08:01PM	Axogen Announces FDA Approval of Biologics License Application for AVANCE (acellular nerve allograft-arwx) (GlobeNewswire) +15.97%
Nov-04-25 07:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 08:15AM	AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates (Zacks) +23.06%
07:13AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-15-25 07:00AM	Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 (GlobeNewswire)
Oct-06-25 08:04AM	CLPT Expands Into Robotic System Supporting Cell and Gene Therapies (Zacks)
Sep-26-25 09:21AM	GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent (Zacks)
Sep-25-25 09:24AM	Masimo Completes Divestment of Consumer Audio Business to HARMAN (Zacks)
Sep-23-25 08:21AM	Here's Why You Should Add Inogen Stock to Your Portfolio Now (Zacks)
Sep-12-25 09:40AM	Are Medical Stocks Lagging AxoGen (AXGN) This Year? (Zacks)
Aug-28-25 09:55AM	Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect? (Zacks)
Aug-27-25 08:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 04:04PM	Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted (Investor's Business Daily) -9.04% +9.60%
10:39AM	FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months (Benzinga)
06:40AM	Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft (GlobeNewswire)
Aug-20-25 09:13AM	Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin (Insider Monkey)
Aug-13-25 12:08PM	Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 (Insider Monkey)
Aug-12-25 09:55AM	Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know (Zacks)
Aug-05-25 08:15AM	AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates (Zacks) +9.32%
07:21AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 07:10AM	Waters (WAT) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 10:00AM	Will PROCEPT BioRobotics Corporation (PRCT) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-29-25 04:10PM	Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
10:00AM	AxoGen (AXGN) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-22-25 04:05PM	Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025 (GlobeNewswire) +8.01% +7.34%
Jul-02-25 10:06PM	Axogen Showcases Nerve Repair Vision at Goldman Sachs (Insider Monkey)
May-28-25 08:00AM	Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-21-25 09:35AM	AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-09-25 09:45AM	Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline (Zacks) -9.73%
09:30AM	MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off (Zacks)
03:08AM	Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ... (GuruFocus.com)
May-08-25 08:30AM	AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -23.18%
07:28AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Reports 2025 First Quarter Financial Results (GlobeNewswire)
07:00AM	Axogen Announces Chief Financial Officer Transition (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
01:09PM	COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised (Zacks)
12:31PM	AxoGen Q1 2025 Earnings Preview (Seeking Alpha)
May-02-25 01:22PM	SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View (Zacks)
01:21PM	DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins (Zacks)
Apr-24-25 08:04AM	Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025 (GlobeNewswire)
Mar-31-25 03:03PM	Stryker Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Mar-25-25 11:12AM	Axogen: LT Bullish, But Outcomes Weighted To Downside, At This Point (SeekingAlpha)
Mar-24-25 08:00AM	Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-25 03:04PM	Alcon Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Feb-26-25 02:03AM	Axogen Inc (AXGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ... (GuruFocus.com)
12:27AM	Q4 2024 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:41AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance) +11.66%
07:10AM	Axogen, Inc. To Host Analyst & Investor Day on March 4th (GlobeNewswire)
07:00AM	Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Feb-11-25 04:58PM	Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 (GlobeNewswire)
Feb-03-25 08:00AM	Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 09:35AM	AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out? (Zacks)
05:05AM	AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last? (Zacks)
Jan-10-25 05:00PM	Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.21%
08:00AM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024 (GlobeNewswire)
Dec-24-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks) -5.41%
Dec-19-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-28-24 12:00PM	All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy (Zacks)
Nov-25-24 09:55AM	How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18% (Zacks)
Nov-08-24 07:35AM	AxoGen Reports Strong Q3 2024 Revenue Growth (TipRanks)
02:08AM	Axogen Inc (AXGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-07-24 07:48AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance) -13.44%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TYNDALL JOSEPH A.	Director	Sep 02 '26	Sale	49.70	3,500	173,940	10,650	Sep 04 04:08 PM
JOSEPH A TYNDALL	Director	Sep 02 '26	Proposed Sale	49.88	3,500	174,580		Sep 02 04:32 PM
Began Marc A	EVP & General Counsel	Aug 10 '26	Option Exercise	8.16	67,500	550,800	117,635	Aug 12 04:13 PM
Began Marc A	EVP & General Counsel	Aug 10 '26	Sale	47.34	67,500	3,195,788	50,135	Aug 12 04:13 PM
Wendell Amy McBride	Director	Aug 11 '26	Option Exercise	14.85	13,353	198,292	121,329	Aug 12 04:12 PM
Wendell Amy McBride	Director	Aug 11 '26	Sale	48.42	13,353	646,592	107,976	Aug 12 04:12 PM
AMY MCBRIDE-WENDELL	Director	Aug 11 '26	Proposed Sale	48.22	13,353	643,882		Aug 11 04:29 PM
Weiler Kathy Johnson	Director	Aug 07 '26	Sale	45.30	14,150	640,967	0	Aug 11 04:15 PM
MARC BEGAN	Officer	Aug 10 '26	Proposed Sale	46.43	67,500	3,134,025		Aug 10 04:32 PM
KATHY WEILER	Director	Aug 07 '26	Proposed Sale	44.35	14,150	627,552		Aug 07 04:37 PM
Levine Alan M	Director	Jun 19 '26	Option Exercise	0.00	14,150	0	50,893	Jun 23 04:37 PM
Weiler Kathy Johnson	Director	Jun 19 '26	Option Exercise	0.00	14,150	0	14,150	Jun 23 04:37 PM
Wendell Amy McBride	Director	Jun 19 '26	Option Exercise	0.00	14,150	0	107,976	Jun 23 04:36 PM
THOMAS PAUL	Director	Jun 19 '26	Option Exercise	0.00	18,867	0	32,395	Jun 23 04:36 PM
TYNDALL JOSEPH A.	Director	Jun 19 '26	Option Exercise	0.00	14,150	0	14,150	Jun 23 04:36 PM
JOHNSON JOHN	Director	Jun 19 '26	Option Exercise	0.00	14,150	0	14,150	Jun 23 04:35 PM
Burke William P. Mr.	Director	Jun 19 '26	Option Exercise	0.00	14,150	0	14,250	Jun 23 04:35 PM
Wendell Amy McBride	Director	May 08 '26	Option Exercise	14.85	1,647	24,458	95,473	May 12 04:06 PM
Wendell Amy McBride	Director	May 08 '26	Sale	42.60	1,647	70,162	93,826	May 12 04:06 PM
AMY MCBRIDE-WENDELL	Director	May 08 '26	Proposed Sale	42.60	1,647	70,163		May 08 04:40 PM
JOHNSON JOHN	Director	May 07 '26	Option Exercise	7.04	11,050	77,792	11,050	May 08 04:07 PM
JOHNSON JOHN	Director	May 07 '26	Sale	43.26	11,050	477,968	0	May 08 04:07 PM
Weiler Kathy Johnson	Director	May 07 '26	Option Exercise	6.95	16,344	113,591	16,344	May 08 04:07 PM
Weiler Kathy Johnson	Director	May 07 '26	Sale	44.09	16,344	720,623	0	May 08 04:07 PM
Kemp Jens	Chief Marketing Officer	May 07 '26	Sale	43.44	4,000	173,761	72,451	May 08 04:07 PM
Hartley Lindsey Marie	CFO	May 07 '26	Option Exercise	8.24	5,463	45,004	65,719	May 08 04:06 PM
Hartley Lindsey Marie	CFO	May 07 '26	Sale	43.67	1,051	45,897	62,756	May 08 04:06 PM
Quackenbush Doris	Sales VP	May 07 '26	Sale	43.51	3,878	168,720	92,416	May 08 04:06 PM
JOHN H JOHNSON	Director	May 07 '26	Proposed Sale	43.26	11,050	477,971		May 07 05:26 PM
DORIS QUACKENBUSH	Vice President of Sales	May 07 '26	Proposed Sale	43.51	3,878	168,719		May 07 04:47 PM
JENS KEMP	Officer	May 07 '26	Proposed Sale	43.44	4,000	173,761		May 07 04:05 PM
KATHY WEILER	Director	May 07 '26	Proposed Sale	44.09	16,344	720,630		May 07 04:05 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 16 '26	Option Exercise	0.00	17,938	0	268,002	Mar 18 04:11 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 16 '26	Sale	32.84	5,221	171,458	262,781	Mar 18 04:11 PM
Hartley Lindsey Marie	CFO	Mar 16 '26	Option Exercise	0.00	9,000	0	62,702	Mar 18 04:10 PM
Began Marc A	EVP & General Counsel	Mar 01 '26	Option Exercise	0.00	11,250	0	54,562	Mar 02 06:15 PM
Wendell Amy McBride	Director	Dec 16 '25	Option Exercise	6.91	43,684	301,963	137,510	Dec 17 04:25 PM
Wendell Amy McBride	Director	Dec 16 '25	Sale	29.31	43,684	1,280,465	93,826	Dec 17 04:25 PM
Weiler Kathy Johnson	Director	Dec 16 '25	Option Exercise	6.99	40,073	280,150	46,653	Dec 17 04:25 PM
Weiler Kathy Johnson	Director	Dec 16 '25	Sale	29.55	46,653	1,378,476	0	Dec 17 04:25 PM
Hartley Lindsey Marie	CFO	Dec 15 '25	Option Exercise	8.27	14,812	122,495	46,188	Dec 17 04:24 PM
Hartley Lindsey Marie	CFO	Dec 15 '25	Sale	29.86	14,812	442,294	31,376	Dec 17 04:24 PM
Amy McBride-Wendell	Director	Dec 16 '25	Proposed Sale	29.31	43,684	1,280,461		Dec 16 05:03 PM
KATHY WEILER	Director	Dec 16 '25	Proposed Sale	29.55	46,653	1,378,484		Dec 16 04:27 PM
LINDSEY MARIE HARTLEY	Officer	Dec 15 '25	Proposed Sale	29.86	14,812	442,294		Dec 15 05:38 PM
DALE MICHAEL D	Chief Executive Officer	Dec 10 '25	Sale	30.00	25,000	750,000	63,537	Dec 12 04:06 PM
Began Marc A	EVP & General Counsel	Dec 11 '25	Sale	30.00	13,222	396,660	18,285	Dec 12 04:05 PM
MARC BEGAN	Officer	Dec 11 '25	Proposed Sale	30.00	13,222	396,660		Dec 11 04:08 PM
DALE MICHAEL D	Chief Executive Officer	Dec 09 '25	Sale	31.21	61,463	1,918,137	88,537	Dec 10 05:21 PM
TYNDALL JOSEPH A.	Director	Dec 09 '25	Option Exercise	8.73	25,108	219,223	25,108	Dec 10 05:20 PM
TYNDALL JOSEPH A.	Director	Dec 09 '25	Sale	30.98	25,108	777,771	0	Dec 10 05:20 PM
DeVinney Erick Wayne	Chief Innovation Officer	Dec 09 '25	Sale	31.21	19,517	609,087	241,132	Dec 10 05:20 PM
Kemp Jens	Chief Marketing Officer	Dec 09 '25	Sale	31.21	8,156	254,532	46,030	Dec 10 05:20 PM
Began Marc A	EVP & General Counsel	Dec 09 '25	Sale	31.21	9,278	289,548	31,507	Dec 10 05:19 PM
THOMAS PAUL	Director	Dec 09 '25	Sale	29.61	21,399	633,710	13,528	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 08 '25	Option Exercise	6.30	11,891	74,913	25,032	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 09 '25	Option Exercise	6.30	8,545	53,834	21,686	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 08 '25	Sale	31.24	23,693	740,203	13,141	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 09 '25	Sale	29.98	21,686	650,190	0	Dec 10 05:19 PM
Hartley Lindsey Marie	CFO	Dec 08 '25	Option Exercise	13.82	25,000	345,400	45,763	Dec 10 05:18 PM
Hartley Lindsey Marie	CFO	Dec 08 '25	Sale	31.56	14,387	454,005	31,376	Dec 10 05:18 PM
MICHAEL DALE	Officer	Dec 10 '25	Proposed Sale	30.00	25,000	750,000		Dec 10 04:19 PM
PAUL THOMAS	Director	Dec 09 '25	Proposed Sale	29.61	21,399	633,710		Dec 09 04:40 PM
JOSEPH A TYNDALL	Director	Dec 09 '25	Proposed Sale	30.98	25,108	777,771		Dec 09 04:39 PM
JOHN H JOHNSON	Director	Dec 09 '25	Proposed Sale	29.98	21,686	650,186		Dec 09 04:05 PM
JOHN H JOHNSON	Director	Dec 08 '25	Proposed Sale	31.24	23,693	740,207		Dec 08 06:21 PM
LINDSEY MARIE HARTLEY	Officer	Dec 08 '25	Proposed Sale	31.56	14,387	454,009		Dec 08 04:32 PM
Burke William P. Mr.	Director	Nov 10 '25	Option Exercise	8.14	19,227	156,508	19,327	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 11 '25	Option Exercise	8.14	3,591	29,231	3,691	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 10 '25	Sale	24.01	19,227	461,640	100	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 11 '25	Sale	24.02	3,591	86,249	100	Nov 13 04:31 PM
WILLIAM BURKE	Director	Nov 11 '25	Proposed Sale	24.00	3,591	86,184		Nov 12 07:05 AM
WILLIAM BURKE	Director	Nov 10 '25	Proposed Sale	23.57	19,227	453,180		Nov 10 04:30 PM
Burke William P. Mr.	Director	Nov 05 '25	Option Exercise	8.14	11,431	93,048	11,531	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 06 '25	Option Exercise	8.14	5,347	43,525	5,447	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 05 '25	Sale	24.05	11,431	274,893	100	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 06 '25	Sale	24.01	5,347	128,371	100	Nov 07 04:52 PM
WILLIAM BURKE	Director	Nov 06 '25	Proposed Sale	23.38	5,347	125,013		Nov 06 04:20 PM
WILLIAM BURKE	Director	Nov 05 '25	Proposed Sale	23.77	11,431	271,715		Nov 05 04:20 PM
Burke William P. Mr.	Director	Oct 30 '25	Option Exercise	7.04	18,248	128,466	18,348	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 30 '25	Sale	23.00	18,248	419,704	100	Oct 31 04:09 PM
WILLIAM BURKE	Director	Oct 30 '25	Proposed Sale	22.25	18,248	406,018		Oct 30 04:16 PM

Axogen, Inc. engages in the development and marketing of surgical solutions for peripheral nerve regeneration and repair. It provides products and educational resources to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Avive Soft Tissue Membrane, AcroVal Neurosensory and Motor Testing System, and AxoTouch Two-Point Discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

PresidentMr. Michael D. Dale

Chief Financial OfficerMs. Lindsey Hartley CPA

Chief Scientific OfficerMr. Erick DeVinney

Executive VPMr. Marc A. Began

Chief Marketing OfficerMr. Jens Schroeder Kemp

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AXGN

Axogen Inc

Upgrade your Finviz experience